Act 126 of 2020 amended the original 2012 Methadone Death and Incident Review (MDAIR) Act, which established the creation of a team to review methadone-related deaths or incidents, to go beyond methadone and include a review of death and incidents related to any Food and Drug Administration (FDA)-approved medication to treat opioid use disorder as a primary, secondary, or contributing factor to a death or incident.

As a result of the new law, the Pennsylvania Department of Drug and Alcohol Programs selected a new MDAIR team to review medication-related deaths, communicate concerns, and develop best practices to prevent future medication-related deaths and incidents.

A list of the new team members can be found here.